Developing a pharmacological treatment for FSHD patients has proven difficult, but since the identification of DUX4-mediated toxicity in muscle from patients, researchers are now focusing on developing therapeutic strategies targeting DUX4. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.